These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32598617)

  • 1. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].
    Malov VA; Ubeeva EA; Ubeeva IP; Nikolaev SM; Umbetova KT
    Ter Arkh; 2019 Nov; 91(11):86-89. PubMed ID: 32598617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
    Sun D; Dai M; Shen S; Li C; Yan X
    Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
    Kiattanaphon A; Vipsoongnern Y; Kunthalert D; Sistayanarain A
    Mol Biol Rep; 2022 Oct; 49(10):9437-9443. PubMed ID: 36002650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antivirals: the endgame for hepatitis C?
    D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
    Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-Free Regimen for Hepatitis C: Insight and Management.
    Masoud MS; Ashfaq UA; Khalid H
    Crit Rev Eukaryot Gene Expr; 2018; 28(4):373-384. PubMed ID: 30311586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.
    Santos APT; Silva VCM; Mendes-Corrêa MC; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; Castro VFD; Pinho JRR; Moreira RC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e61. PubMed ID: 36197422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of RASs /RVs in the Current Management of HCV.
    Malandris K; Kalopitas G; Theocharidou E; Germanidis G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
    Pawlotsky JM
    Gastroenterology; 2016 Jul; 151(1):70-86. PubMed ID: 27080301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HCV protease inhibitors and drug resistance].
    Pawłowska M; Olczak A
    Przegl Epidemiol; 2012; 66(1):55-7. PubMed ID: 22708299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
    Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
    J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to direct-acting antiviral agents: clinical utility and significance.
    Cento V; Chevaliez S; Perno CF
    Curr Opin HIV AIDS; 2015 Sep; 10(5):381-9. PubMed ID: 26248125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients.
    Hasanshahi Z; Hashempour A; Ghasabi F; Moayedi J; Musavi Z; Dehghani B; Sharafi H; Joulaei H
    BMC Gastroenterol; 2021 Nov; 21(1):443. PubMed ID: 34819046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.